Pharmaceutical Boehringer Ingelheim today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia, with Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). 3 January 2019